# Phase I Pharmacokinetic Study (SALBLOCK)

> **NCT01564199** · PHASE1 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** salmeterol / fluticasone propionate

## Key facts

- **NCT ID:** NCT01564199
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01564199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01564199, "Phase I Pharmacokinetic Study (SALBLOCK)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01564199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*